In plain words
A drug company prepares a dossier and pays fees to register a generic medicine with a regulator such as the SFDA. The question is whether these costs are an asset or an expense. Earlier research costs are expensed. Direct registration costs are capitalised as an intangible asset only once all development criteria are met, then amortised over the expected selling life. If the filing is rejected, the asset is written off immediately.
Why it matters
Getting the research/development boundary wrong for registration costs either expenses genuine assets (understating equity and future margins) or capitalizes speculative filing costs that should be written off if rejected, overstating assets. Because a rejected or withdrawn filing must be written off immediately, weak capitalization discipline creates a hidden impairment risk that surfaces suddenly and can surprise investors.
Diagnostic questions
Has the product moved from the research stage into a development stage with a technically feasible, identifiable formulation or device, not merely a research idea? Is management's commitment to completing and marketing the registered product evidenced by an approved budget and allocated resources, not just intent? Can the direct filing, dossier and bioequivalence/clinical costs tied to this specific registration be measured reliably and separated from general R&D expense? If the filing is later rejected or withdrawn, is there a plan to write off the capitalized balance immediately?
Recognition
1) Confirm the product has moved from the research stage into a development stage with a technically feasible, identifiable product (not merely a research idea). 2) Confirm management is committed to completing and marketing the registered product, supported by budget approval and resource allocation. 3) Identify and isolate direct costs of the registration/authorization process (filing fees, dossier preparation, bioequivalence/clinical studies tied directly to the filing). 4) Capitalize only from the point all IAS 38 development criteria are met simultaneously (technical feasibility, intent, ability, probable future benefit, resources available, reliable measurement); expense all earlier-stage research costs as incurred. 5) If an application is rejected or withdrawn, write off the capitalized amount immediately as an impairment/expense. 6) Reassess capitalized registration intangibles for impairment on any adverse regulatory or market development.
Measurement
Measure at cost including filing fees and directly attributable third-party costs (dossier preparation, required bioequivalence/clinical studies tied to the filing); exclude general overhead not directly attributable. Amortize over the useful life considering patent life, expected market exclusivity and realistic renewal patterns, not an indefinite life unless renewal is virtually automatic at negligible cost (rare in pharma regulatory practice). Test for impairment whenever an indicator arises (e.g. competitor approval, adverse regulatory finding), in addition to at least annual review of the amortization period and method.
Presentation & disclosure
Disclose the carrying amount of registration intangibles by product or product family; disclose the amortization method and period and the basis for the useful life estimate (patent life, exclusivity, renewal pattern); disclose amounts written off during the period for rejected/withdrawn applications; disclose any authorizations tested for impairment following adverse regulatory or market developments and the outcome.
Common mistakes
- Capitalizing all R&
- D spend once a registration application is merely filed, before development criteria are objectively met
- treating registration intangibles as having an indefinite useful life without justification (renewal is rarely virtually automatic at negligible cost in pharma)
- failing to write off capitalized costs promptly when an application is rejected or withdrawn
- capitalizing general R&
- D overhead allocations rather than only directly attributable filing costs
- ignoring impairment indicators such as a competitor'
- s earlier approval or a negative regulatory signal.
Simple example
A pharmaceutical company incurs SAR 2,500,000 in dossier preparation and SFDA filing fees for a generic product that has completed bioequivalence studies and is expected to be approved and sold for at least 8 years. As costs are incurred and criteria are met: Dr Intangible asset - product registration 2,500,000 / Cr Cash/Payable 2,500,000. Annual amortization over the 8-year expected life: Dr Amortization expense 312,500 / Cr Accumulated amortization - product registration 312,500. If the SFDA subsequently rejects the filing: Dr Impairment loss (P&L) 2,500,000 (net of accumulated amortization to date) / Cr Intangible asset - product registration (net carrying amount, fully written off).
Professional judgment
Distinguishing the research phase from the development phase, and judging probability of regulatory approval and future economic benefit, are inherently judgmental in pharma, bioequivalence success for a generic is a stronger objective indicator than early-stage novel compound filings, so the same capitalization policy should not be applied uniformly across generic and innovator products. Estimating useful life (tied to patent/exclusivity remaining life and realistic renewal expectations) also requires product-specific analysis rather than a standard company-wide period.
Source basis
IAS 38 · Intangible Assets
Paragraph references
Verified against the official standard texts used in the IFRS Expert skill.
Related issues
Educational and navigation content only. Not professional advice. Does not reproduce official IFRS/IAS text. Consult the authoritative standards and qualified professionals; professional judgment may still be required.